Isoniazid monoresistantance - impact on treatment outcomes in patients with pulmonary tuberculosis

dc.contributor.author	Mironov, Tatiana
dc.contributor.author	Donica, Ana
dc.date.accessioned	2020-07-10T12:38:25Z
dc.date.available	2020-07-10T12:38:25Z
dc.date.issued	2018
dc.identifier.citation	MIRONOV, Tatiana, DONICA, Ana. Isoniazid monoresistantance - impact on treatment outcomes in patients with pulmonary tuberculosis. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 84-85.	en_US
dc.identifier.uri	https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf
dc.identifier.uri	http://repository.usmf.md/handle/20.500.12710/11231
dc.description	Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova, Chiril Draganiuc Pneumophthysiology Institute of the Republic of Moldova	en_US
dc.description.abstract	Introduction. Isoniazid monoresistance is the most common type of single TB drug resistance worldwide. There is no strong evidence regarding the best treatment regimens in this group of patients.	en_US
dc.language.iso	en	en_US
dc.publisher	MedEspera	en_US
dc.subject	susceptible TB	en_US
dc.subject	treatment outcomes	en_US
dc.subject	treatment regimens	en_US
dc.title	Isoniazid monoresistantance - impact on treatment outcomes in patients with pulmonary tuberculosis	en_US
dc.type	Article	en_US